Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENLON-PLUS vs ATIVAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Enlon-Plus (neostigmine methylsulfate and glycopyrrolate) is a combination of a reversible acetylcholinesterase inhibitor (neostigmine) and an anticholinergic agent (glycopyrrolate). Neostigmine inhibits acetylcholinesterase, increasing acetylcholine concentration at cholinergic synapses, enhancing neuromuscular transmission. Glycopyrrolate counteracts muscarinic side effects (e.g., bradycardia, excessive secretions) without affecting nicotinic actions.
Benzodiazepine that potentiates GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
Reversal of non-depolarizing neuromuscular blocking agents after surgery,Off-label: Treatment of myasthenia gravis (neostigmine component)
Anxiety disorders,Short-term relief of anxiety symptoms,Status epilepticus (IV),Preanesthetic medication (IM/IV)
1 to 2 m L (0.5 to 1 mg neostigmine methylsulfate with 0.2 to 0.4 mg glycopyrrolate) IV over 1 minute; may repeat in 10-15 minutes if needed; maximum total dose: 5 m L.
2-3 mg orally divided 2-3 times daily; up to 10 mg/day. IV: 2 mg slow IV push, may repeat in 1-2 hours; max 10 mg/day. IM: 0.05 mg/kg (max 4 mg) 2-4 hours before procedure.
Terminal elimination half-life: 3.5–4.5 hours (prolonged in hepatic impairment).
Terminal elimination half-life is 12–18 hours (mean ~14 h). In elderly, hepatic impairment, or obesity, half-life may be prolonged up to 30 hours.
Neostigmine: Hydrolyzed by cholinesterases and metabolized in the liver via microsomal enzymes. Glycopyrrolate: Not significantly metabolized; eliminated unchanged in urine and bile.
Hepatic via glucuronidation (UGT2B15, UGT2B7); major metabolite is lorazepam glucuronide (inactive).
Renal: 70% unchanged; biliary/fecal: 30% as metabolites.
Renal: lorazepam is primarily excreted as inactive glucuronide conjugates; <1% is excreted unchanged. Total: ~95% excreted in urine, ~5% in feces.
Plasma protein binding: 55–65%, primarily to albumin.
91% ± 2% bound to albumin. Binding is linear over therapeutic concentrations and not saturable.
Vd: 0.8–1.2 L/kg, indicating distribution into total body water.
1.3 ± 0.2 L/kg. Vd increases with obesity, hepatic cirrhosis, and in elderly patients, indicating extensive tissue distribution.
Oral: 70–80% (first-pass effect); IM: 100%.
Oral: 90% (range 80–100%) with first-pass metabolism negligible; Sublingual: ~90%; Intramuscular: 100% (absolute bioavailability).
Cr Cl 10-50 m L/min: Use 50% of dose. Cr Cl <10 m L/min: Use 25% of dose. Adjust based on neostigmine component due to renal excretion.
Cr Cl 10-50 m L/min: reduce dose by 50% or increase interval; Cr Cl <10 m L/min: avoid or reduce dose by 50-75% with caution.
No specific adjustment required; neostigmine minimally hepatically metabolized.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid or reduce dose by 50-75% with monitoring.
0.04 mg/kg neostigmine methylsulfate with 0.02 mg/kg glycopyrrolate IV; may repeat in 10-15 minutes if needed; maximum single dose: 2 m L.
Children ≥6 months: 0.02-0.05 mg/kg/dose IV/IM (max 2 mg) for status epilepticus; PO: 0.05-0.1 mg/kg/dose (max 2 mg) 2-4 times daily.
Use with caution; consider lower initial doses due to potential renal impairment; monitor for bradycardia and excessive cholinergic effects.
Initiate at 0.5-1 mg orally daily in divided doses; increase slowly; max 2 mg/day. IV/IM: 0.5-1 mg initial; avoid doses >2 mg due to increased sedation risk.
Should be used only when facilities for immediate endotracheal intubation, artificial respiration, and oxygen therapy are available. Bradycardia and cardiac arrest have occurred. Administer in the presence of an anesthesiologist or other qualified clinician.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.
Risk of severe bradycardia, hypotension, and cardiac arrest. Use caution in patients with asthma, epilepsy, bradyarrhythmias, recent myocardial infarction, or hyperthyroidism. May increase bronchial secretions. Avoid in patients with mechanical obstruction of the gastrointestinal or urinary tract.
Respiratory depression risk,Dependence and withdrawal syndrome,Abuse potential,Paradoxical reactions (hyperactivity, aggression),Use with caution in hepatic impairment,Elderly at increased risk for sedation and falls
Known hypersensitivity to neostigmine, glycopyrrolate, or any component. Contraindicated in patients with peritonitis, mechanical intestinal obstruction, or urinary tract obstruction.
Hypersensitivity to lorazepam or any benzodiazepine,Acute narrow-angle glaucoma,Severe respiratory insufficiency,Myasthenia gravis,Concurrent use with opioids (absolute unless alternative unavailable)
No specific food interactions are reported. Maintain adequate hydration. Avoid excessive caffeine or alcohol, which may affect heart rate or fluid balance.
No specific food interactions. However, grapefruit juice may increase lorazepam levels (minor interaction). Avoid excessive caffeine as it may reduce sedative effects.
First trimester: No adequate studies in pregnant women; animal studies not available. Risk cannot be ruled out. Second/third trimester: Potential fetal toxicity (respiratory depression, bradycardia) if used near term. Avoid use during labor due to risk of neonatal respiratory depression.
First trimester: Increased risk of oral clefts (odds ratio 1.5–2.0); second and third trimesters: Risk of hypotonia, respiratory depression, and withdrawal symptoms in neonate; avoid in first trimester if possible; use lowest effective dose.
Not recommended. Unknown M/P ratio. Atropine and pralidoxime (components of ENLON-PLUS) may enter breast milk; potential for infant anticholinergic effects and gastrointestinal disturbances.
Enters breast milk; M/P ratio approximately 0.2–0.5; avoid or use with caution due to infant sedation and feeding difficulties; monitor for drowsiness and weight gain.
No established dose adjustments. Increased plasma volume and renal clearance in pregnancy may reduce drug concentrations; however, no pharmacokinetic studies available. Titrate to effect with caution.
Increased clearance and volume of distribution in pregnancy may necessitate dose increase; monitor clinical response; use lowest effective dose; avoid late third trimester if possible.
ENLON-PLUS (neostigmine/glycopyrrolate) is used for reversal of non-depolarizing neuromuscular blockade. Neostigmine inhibits acetylcholinesterase, increasing ACh at the neuromuscular junction; glycopyrrolate is an anticholinergic to counteract muscarinic side effects (bradycardia, excessive secretions). Monitor heart rate closely; glycopyrrolate may cause tachycardia. Administer IV slowly over 1 minute. Onset is 5-10 minutes; peak effect at 10-20 minutes. Use with caution in patients with bradycardia, asthma, or peptic ulcer disease.
ATIVAN (lorazepam) is a benzodiazepine with intermediate onset and duration; useful for status epilepticus (IV) and preoperative anxiolysis. Monitor for respiratory depression, especially when combined with opioids. Not ideal for long-term anxiety due to tolerance and dependence risk. Use with caution in elderly (increased fall risk).
This medication is given to reverse muscle relaxants after surgery.,You may experience changes in heart rate; tell your doctor if you feel palpitations or chest discomfort.,Dry mouth and blurred vision are possible side effects due to the glycopyrrolate component.,Inform your healthcare provider if you have a history of heart problems, asthma, or stomach ulcers.,You may feel temporary muscle weakness or twitching as the medication works.
Do not drive or operate machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants while taking ATIVAN.,Take exactly as prescribed; do not increase dose or stop abruptly without consulting your doctor.,May cause drowsiness, dizziness, or blurred vision.,Report any unusual mood changes, confusion, or respiratory difficulty.,This medication can be habit-forming; prolonged use may lead to dependence.,Notify your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENLON-PLUS vs ATIVAN, answered by our medical review team.
ENLON-PLUS is a Cholinesterase Inhibitor Combination that works by Enlon-Plus (neostigmine methylsulfate and glycopyrrolate) is a combination of a reversible acetylcholinesterase inhibitor (neostigmine) and an anticholinergic agent (glycopyrrolate). Neostigmine inhibits acetylcholinesterase, increasing acetylcholine concentration at cholinergic synapses, enhancing neuromuscular transmission. Glycopyrrolate counteracts muscarinic side effects (e.g., bradycardia, excessive secretions) without affecting nicotinic actions.. ATIVAN is a Benzodiazepine that works by Benzodiazepine that potentiates GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENLON-PLUS and ATIVAN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENLON-PLUS is: 1 to 2 m L (0.5 to 1 mg neostigmine methylsulfate with 0.2 to 0.4 mg glycopyrrolate) IV over 1 minute; may repeat in 10-15 minutes if needed; maximum total dose: 5 m L.. The standard adult dose of ATIVAN is: 2-3 mg orally divided 2-3 times daily; up to 10 mg/day. IV: 2 mg slow IV push, may repeat in 1-2 hours; max 10 mg/day. IM: 0.05 mg/kg (max 4 mg) 2-4 hours before procedure.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENLON-PLUS and ATIVAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENLON-PLUS is classified as Category C. First trimester: No adequate studies in pregnant women; animal studies not available. Risk cannot be ruled out. Second/third trimester: Potential fetal toxicity (respiratory depres. ATIVAN is classified as Category C. First trimester: Increased risk of oral clefts (odds ratio 1.5–2.0); second and third trimesters: Risk of hypotonia, respiratory depression, and withdrawal symptoms in neonate; avo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.